Comparative Pharmacology
Head-to-head clinical analysis: ENALAPRIL MALEATE versus UNIVASC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENALAPRIL MALEATE versus UNIVASC.
ENALAPRIL MALEATE vs UNIVASC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Enalapril is a prodrug that is hydrolyzed to enalaprilat, a potent competitive inhibitor of angiotensin-converting enzyme (ACE), blocking the conversion of angiotensin I to angiotensin II, reducing vasoconstriction, aldosterone secretion, and sodium/water retention.
Angiotensin-converting enzyme (ACE) inhibitor; inhibits conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure.
Initial: 5 mg orally once daily; titrate to 10-40 mg/day in 1-2 divided doses. Target: 10-40 mg/day. Maximum: 40 mg/day. Route: Oral. Frequency: Once or twice daily.
Initial: 7.5 mg orally once daily; titrate to 15-30 mg once daily. Maximum: 60 mg/day.
None Documented
None Documented
Terminal elimination half-life of enalaprilat (active metabolite) is approximately 35-38 hours. This prolonged half-life supports once-daily dosing in most patients, but may require dosage adjustment in renal impairment.
The terminal elimination half-life of moexiprilat, the active metabolite, is approximately 9.8 hours in patients with normal renal function. This supports once-daily dosing, though the antihypertensive effect may persist beyond 24 hours with continued therapy.
Primarily renal (60-80% as unchanged drug and metabolites, mainly enalaprilat); biliary/fecal excretion accounts for the remainder (approximately 20-30%).
Univasc (moexipril) is primarily eliminated via renal excretion (approximately 50% of absorbed dose as unchanged drug and metabolites) and fecal excretion (about 50%).
Category D/X
Category C
ACE Inhibitor
ACE Inhibitor